Skip to main content
uniQure N.V. logo

uniQure N.V. — Investor Relations & Filings

Ticker · QURE ISIN · NL0010696654 LEI · 724500RPCTZLFYJZ3S98 US Manufacturing
Open in API
Filings indexed 859 across all filing types
Latest filing 2017-09-22 Director's Dealing
Country NL Netherlands
Listing US QURE

About uniQure N.V.

https://www.uniqure.com/

uniQure N.V. is a gene therapy company focused on developing and commercializing treatments for patients with rare and severe diseases. The company utilizes its adeno-associated virus (AAV) based technology platform to create single-administration therapies with the potential for curative results. Its research and development pipeline is concentrated on liver-directed and central nervous system (CNS) disorders, with a key clinical program targeting Huntington's disease. uniQure aims to deliver transformative medicines by translating scientific innovation into viable treatments.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2017-09-22 English
FORM 4 SUBMISSION
Director's Dealing
2017-09-22 English
FORM 3 SUBMISSION
Director's Dealing
2017-09-22 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 15, 2017, reporting the entry into a material definitive agreement. The content describes a Sales Agreement for an at-the-market offering program with Leerink Partners LLC, including details about the offering, commission, and legal opinions. There are no financial statements or quarterly/yearly financial results presented, nor is this a transcript, proxy, or governance document. The primary focus is on a financing activity (sale of shares) and the agreement related to it. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is 7066 characters, which is sufficient to contain substantive information about the financing agreement rather than just an announcement or a brief notice.
2017-09-18 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an offering of up to 5,000,000 ordinary shares. It includes detailed information about the offering, use of proceeds, risk factors, plan of distribution, and legal matters. The document is not a financial report, earnings release, or management discussion, but rather a capital raising document describing the terms and conditions of a share offering. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities.
2017-09-18 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated September 14, 2017. The key content is the submission of matters to a vote of securityholders at an Extraordinary General Meeting (EGM), specifically the voting results on the appointment of non-executive directors. The document provides detailed voting results for agenda items related to board appointments. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3860 characters, which is relatively short but contains actual voting results, not just an announcement of a report. Therefore, it is not a Report Publication Announcement (RPA). It is not a management change announcement (MANG) because it reports voting results, not the appointment itself. Hence, the correct classification is DVA with high confidence.
2017-09-14 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.